ISIDOG

SCYNEXIS to Present Pooled Data Analysis Results Demonstrating Consistent Efficacy and Safety Outcomes Across Two Phase 3 VANISH Clinical Trials of Oral Ibrexafungerp Therapy for Vaginal Yeast Infection at October Medical Conferences

Retrieved on: 
Wednesday, October 13, 2021
CQD, Most, Candida glabrata, Food, Vaginitis, Incidence, Vagina, International Society for Infectious Diseases, Administration, Candidiasis, Dizziness, Drug of last resort, CYP3A, Congress, Embarrassment, Women's health nurse practitioner, Nurse practitioner, Pain, Depression, International Society, NDA, Safety, Infection, Oral, Tablet, Woman, Abdominal pain, New Drug Application, Birth, Conference, Nausea, Diarrhea, FDA, Patient, Vaginal yeast infection, Pregnancy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, Biotechnology, ISIDOG, Vomiting, Medical Affairs Bureau, Anxiety, NASDAQ, Candida albicans, Pharmaceutical industry, Birth control, Dietary supplement

We are deeply committed to innovation in the field of womens health and are extremely pleased to be able to share this additional pooled data analysis from our groundbreaking VANISH clinical research.

Key Points: 
  • We are deeply committed to innovation in the field of womens health and are extremely pleased to be able to share this additional pooled data analysis from our groundbreaking VANISH clinical research.
  • 24th Annual NPWH Premier Womens Healthcare Conference, October 13-16, 2021
    Title: BREXAFEMME (ibrexafungerp tablets) A Novel, Oral Treatment for Vulvovaginal Candidiasis
    Title: Efficacy and Safety of Oral Ibrexafungerp in Subjects with Vulvovaginal Candidiasis: Pooled Data from Two Phase 3, Randomized, Blinded, Study vs.
  • Meeting attendees can view the conference sessions and posters on demand until January 12, 2022.
  • In addition, late-stage clinical investigation of ibrexafungerp for the prevention of recurrent vulvovaginal candidiasis (rVVC) and the treatment of life-threatening invasive fungal infections in hospitalized patients is ongoing.